The Benign Prostatic Hyperplasia Devices Market research report provided by Data Bridge Market research gives the market division on the basis of type, market size, product shipments, and applications. He singles out the global reception of the articles as one of the development factors, driven by the accessibility of the article. The Global Review Report gives a concise summary of the major players working on the research, their article offering, major events, business practicality, and feedback. This Benign Prostatic Hyperplasia Devices Market report which is the result of definitive engagement by industry specialists, contains a wealth of information that can benefit anyone, regardless of their business or business. of their scientific interest.
Global Benign Prostatic Hyperplasia Devices Market is expected to reach a CAGR of 12.2% during the forecast period of 2019 to 2026.
Download a sample PDF copy of the report @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-benign-prostatic-hyperplasia-devices-market
Some of the major players operating in this market are KARL STORZ SE & Co. KG, Olympus Corporation, Richard Wolf GmbH, Lumenis, Urologix, LLC, Boston Scientific Corporation, Coloplast Corp, LISA Laser Products GmbH, Medifocus, Inc., Coloplast Corp. , Teleflex Incorporated, Urotech Devices, BD, PROCEPT BioRobotics Corporation, Biolitec AG and others.
Purpose of the report:
The report strives to provide all the insights on the Benign Prostatic Hyperplasia Devices market along with all the CAGR values ââand market share analysis of all market players. The report is vital market information which explains entire competitive landscape and all market segments while analyzing and forecasting the Benign Prostatic Hyperplasia Devices market for the years to come. The report also provides all the details in terms of recent developments in the market and all manufacturers.
The Benign Prostatic Hyperplasia Devices Market report presents an in-depth study of the market with respect to the revenue and development patterns of the business sector. This statistical survey report also integrates advanced review and gauge for different market sections and all geographic districts including North America, South America, Asia & Pacific region, Middle East , Africa and Europe. The report further includes income; the size, share, volume of creation and use of the industry to gain experiences on government issues and tackling a huge part of the industry as a whole.
This report on the Benign Prostatic Hyperplasia Devices Market provides an important source of wisdom for business tacticians and serious consideration of the global market. It gives the industry insight into the development review and advanced spending. This Benign Prostatic Hyperplasia Devices market research report guides you in beating the upcoming deterrents in the business. Different analytical instruments like SWOT review, Porters Five Power survey, PESTLE analysis are used to acquire the important market data. Finally, the research report provides comprehensive information that improves the agreement, extension and use of the report.
The global benign prostatic hyperplasia devices market is segmented on the basis of procedure type and end user.
On the basis of procedure type, the market is segmented into Transurethral Prostate Resection (TURP), Prostatic Urethral Lift, Prostatectomy, Laser Surgery, Transurethral Microwave Therapy (TUMT), Transurethral Prostate Ablation needle (TUNA), prostate stenting / implants and others. Laser surgery is sub-segmented into holmium lasers, green light laser / PVP, and thulium laser based devices. The others segment is sub-segmented into Water Induced Heat Therapy, High Frequency Ultrasound (HIFU), Prostatic Artery Embolization (PAE) and others. In 2019, the Transurethral Prostate Resection (TURP) segment is expected to lead the market with 25.1% market share, while the prostatic urethral lift segment will reach the highest CAGR of 13.1% in 2019. during the forecast period 2019 to 2026.
On the basis of end user, the market is segmented into hospitals and clinics and outpatient surgery centers. In 2019, the hospital and clinic segment is expected to dominate with 77.9% market share and achieve the highest CAGR of 12.5% ââduring the forecast period of 2019 to 2026.
- Market segmentation
- Market Snapshot
- Premium previews
- By component
- type of product
- type of industry
- North America
- Asia Pacific
- South America
- Middle East and Africa
- Business landscape
- Company Profiles
- Associated reports
In February 2019, Coloplast Corp signed a three-year group purchasing agreement for general urology products with Premier, Inc. (US). This agreement helps the company distribute its products through Premier, Inc. This will help further market expansion.
In January 2019, Richard Wolf GmbH presented the innovative system solutions at ARAB HEALTH from January 28 to 31 for minimally invasive human drugs. This would help improve the company’s customer base.
In November 2018, Teleflex Incorporated’s subsidiary, Neotract, Inc. (US) received clearance from the Ministry of Health, Labor and Welfare (MHLW) of Japan. This regulatory approval will be a milestone for NeoTract, as it will allow the UroLift system to be an alternative to physicians who treat BPH in Japan. This will allow the business to generate more income.
In November 2018, Olympus Corporation announced its investment in the Israeli company with Medi-Tate Ltd., a manufacturer of minimally invasive devices for benign prostatic hyperplasia. This investment has enabled the company to strengthen its support in the field of urology with expanded options in improved patient care as well as offerings that complement the strong portfolio of BPH.
In November 2018, Karl Storz installed a hybrid operating room at Tungs Taichung MetroHarbor Hospital in Taiwan. This can be used as a room for minimally invasive surgery, one for robotic surgery, and operating rooms for critical and acute care. This strategy would help improve the company’s customer base.
In September 2018, Boston Scientific acquired a privately held Augmenix, Inc. (US). Augmenix, Inc. has developed a SpaceOAR system specifically designed for therapy used to alleviate the common and unbearable side effects of radiation therapy for prostate cancer. The acquisition will strengthen the company’s positioning in the market and SpaceOAR hydrogel is an essential addition to prostate health treatment products.
Key points of the report:
- Historical and current market size and projection to 2028
- Market trends impacting the growth of the Global Taste Modulator Market
- Analyze and forecast the Taste Modulator market based on application and type.
- Trends in key regional and national markets for processes, derivatives and applications
- Company profiling of key players which includes business operations, products and services, geographic presence, recent developments and key financial analysis
Main advantages of purchasing the report
The report identifies and discusses key markets for Benign Prostatic Hyperplasia Devices market operations and services market, which would help equipment manufacturers and service providers examine the growth in demand.
The report helps system vendors understand the pulse of the market and provides insights into the drivers, restraints, opportunities, and challenges.
The report will help key players better understand their competitors’ strategies and help the min to make better strategic decisions.
About the Data Bridges Market Research:
An absolute way to predict what the future holds is to understand the trend today!
Data Bridge has established itself as an unconventional, neoteric market research and consulting company with an unprecedented level of resilience and integrated approaches. We are committed to finding the best market opportunities and promoting effective information for your business to thrive in the market. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process.
Market research on data bridges
United States: +1 888 387 2818
UK: +44 208 089 1725
Hong-Kong: +852 8192 7475
Email @ [email protected]